PHCUF 10.85 Stock Price Photocure ASA
Range: | 4.47-6.5 | Vol Avg: | 88 | Last Div: | 0 | Changes: | -0.27 |
Beta: | 0.99 | Cap: | 0.12B | Currency: | USD | Exchange: | PNK |
Sector: | Healthcare | IPO: | Tue Sep 24 2013 | Empoloyees: | 102 |
CUSIP: | | CIK: | | ISIN: | NO0010000045 | Country: | NO |
CEO: | Mr. Daniel Schneider | Website: | https://www.photocure.com |
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.